GIGABYTE-TECHNOLOGY
3.6.2024 11:31:29 CEST | Business Wire | Press release
Renowned globally for its research and development capabilities, GIGABYTE Technology will exhibit its products and solutions at COMPUTEX from June 4 to June 7 under the theme "ACCEVOLUTION," acclaiming the new era of accelerated-computing and time of AI. AI remains a major trend, attracting industry leaders, including the highest number of CEOs in COMPUTEX history. In celebration, Taipei 101 will be illuminated for COMPUTEX, with GIGABYTE lighting it up on June 4 from 6:30 PM to 10:00 PM, promoting the AI event and welcoming international guests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602653282/en/
Shining Bright atop Taipei 101, GIGABYTE Redefines AI Evolution Accelerated by Next-Generation Computing at COMPUTEX (Photo: Business Wire)
Prominent leaders in global chip development will attend COMPUTEX, aiming to assert their influence in the AI era and strengthen ties with the Taiwanese supply chain. GIGABYTE, an integral part of this industry, is honored to invite these CEOs to its booth to explore the latest technologies. GIGABYTE's diverse product lineup spans the entire AI lifecycle, featuring industry-leading technologies and flexible server solutions. These products, designed to meet future computing demands with advanced cooling solutions, will be showcased on an unprecedented scale at COMPUTEX. Additionally, GIGABYTE will present its Red Dot Award-winning PC products, new products demos, and AI experiences for gamers and creators.
GIGABYTE has consistently been the fastest to market with the most diverse range of AI servers. This year, the G593 flagship AI server series, known for its high-density features and flexible design, is displayed to support NVIDIA's next-gen chips H200 and B100, as well as models designed for AMD's MI300X. The showcase will also feature the new X series servers, based on NVIDIA's MGX modular design, which shortens development times and accelerates data center deployment. Customers can choose between AMD EPYC, Intel Xeon x86 CPUs, or NVIDIA Grace Hopper Arm superchips, offering tailored configurations for specific computational needs.
Large Language Models (LLM) have become increasingly popular in AI. To handle the growing number of parameters, GIGABYTE is showcasing servers supporting NVIDIA's latest Blackwell architecture, featuring the highly acclaimed high-density designs with the powerful B100 and B200 superchips. The B100 will be compatible with the G593 series hardware, while the B200's next-level performance introduces thermal challenges beyond the capacity of traditional air cooling. GIGABYTE has addressed this with its industry-leading thermal engineering by employing direct liquid cooling. The highly anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as the GB200 NVL72, acting as a massive GPU that can achieve 30 times the inference performance of an equivalent number of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions about the future of AI development and computing deployment.
Introducing GIGA POD, GIGABYTE’s one-stop rack integration solution leveraging its 20+ years of server proficiency and experience gained from CSP partnerships. GIGA POD is a complete system integration including architecture planning, equipment integration, software installation, and post-deployment testing. It offers different configurations of AI servers with NVIDIA SXM or AMD Instinct GPUs or NVIDIA Superchips and is gradually expanding to future top-tier GPU-equipped AI servers. GIGA POD is also a prime demonstration of GIGABYTE’s thermal engineering, fitting an HGX module in a 5U chassis of an air-cooled G593 server. Such dense server enables customers the option to choose either a 9-rack configuration with 4 AI servers per 42U rack or a 5-rack configuration with 8 AI servers per 48U rack, achieving nearly double the utilization space and greatly improving resource efficiency. GIGABYTE has also invited Northern Data Group, a key client of its cluster computing solution (GIGA POD) and Europe’s largest generative AI cloud service provider, to participate in a special event "Executive Dialogue with AI Visionaries" with the General Manager of GIGABYTE's subsidiary, Giga Computing. The live conversation will cover the collaboration, keys to success, and perspectives on the future of AI.
AI development extends beyond GPU computations to comprehensive data center infrastructure, including storage and network transmission. GIGABYTE's R&D expertise in thermal, mechanical, and modular design ensures a diverse product range across IT architectures. At COMPUTEX, GIGABYTE will showcase servers for cloud and edge computing, high-performance, and high-density storage. Additionally, general-purpose servers for SMBs and DIY server motherboards for micro-enterprises and individuals will be displayed, supporting AI development at all scales.
GIGABYTE has pioneered advanced cooling solutions, mastering technologies like direct liquid and immersion cooling. With expertise in cross-disciplinary integration, GIGABYTE has developed its own cold plates, DLC racks, and immersion tanks, offering comprehensive cooling solutions. At COMPUTEX, GIGABYTE will showcase single-phase immersion cooling, direct liquid cooling, and a new rear-door heat exchanger (RDHx) cooling rack. Collaborating with nVent, GIGABYTE deployed Spain's third-ranked supercomputer, Hyperion, using full-rack servers with RDHx. This setup, connected to an outdoor chiller, delivers up to 54,000 watts of heat dissipation per hour, reducing air conditioning needs and effectively managing computational hotspots.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
The rise of AI is transforming personal computing. GIGABYTE's Z790 series motherboards are designed for different scenarios, and support RTX 40 SUPER series graphics cards, deliver peak performance with enhanced core counts, VRAM, and memory speeds. Utilizing AI acceleration, the graphics cards offer exceptional computing and graphics processing for both professional tasks and AAA gaming, while preparing users for new AI-driven applications. The AORUS 17X and 16X AI laptops feature GIGABYTE's AI Nexus with AI Boost, AI Generator, and AI Power Gear, providing improved performance, seamless AI generation, and extended battery life. At our booth's AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602653282/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
